Angiotensin-converting enzyme (ACE) inhibitors for proteinuria and microalbuminuria in people with sickle cell disease-Reference-Cited by-同舟云学术

Angiotensin-converting enzyme (ACE) inhibitors for proteinuria and microalbuminuria in people with sickle cell disease

Published:2015-06-04 Issue: Volume: Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Sasongko Teguh H¹,Nagalla Srikanth²,Ballas Samir K³

Affiliation:

1. International Medical University; Human Biology Division, School of Medicine; No. 126, Jalan Jalil Perkasa 19, Bukit Jalil Kuala Lumpur Malaysia 57000

2. Thomas Jefferson University; Department of Medicine, Division of Hematology; Medical Center Boulevard 1015 Walnut Street Philadelphia Pennsylvania USA PA 19107-5099

3. Jefferson Medical College, Thomas Jefferson University; Cardeza Foundation for Hematologic Research, Department of Medicine; 1015 Walnut Street Philadelphia USA PA 19107-5099

Publisher

Wiley

Subject

Pharmacology (medical)

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/14651858.CD009191.pub3/fullpdf

Reference60 articles.

1. A randomized trial of captopril for microalbuminuria in normotensive adults with sickle cell anemia;Foucan;American Journal of Medicine,1998

2. Enalapril reduces the albuminuria in patients with sickle cell disease;Aoki;American Journal of Medicine,1995

3. Prevalence and pathologic features of sickle cell nephropathy and response to inhibition of angiotensin-converting enzyme;Falk;New England Journal of Medicine,1992

4. Enalapril and hydroxyurea therapy for children with sickle nephropathy;Fitzhugh;Pediatric Blood and Cancer,2005

5. Prevalence, prevention, and treatment of microalbuminuria and proteinuria in children with sickle cell disease;McKie;Journal of Pediatric Hematology/Oncology,2007

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Blockade of the mineralocorticoid receptor improves markers of human endothelial cell dysfunction and hematological indices in a mouse model of sickle cell disease;The FASEB Journal;2023-07-21

2. Epidemiology and Outcomes of Glomerular Diseases in Low- and Middle-Income Countries;Seminars in Nephrology;2022-09

3. Considerations for the future: current and future treatment paradigms with mineralocorticoid receptor antagonists—unmet needs and underserved patient cohorts;Kidney International Supplements;2022-04

4. Reduced blood pressure in sickle cell disease is associated with decreased angiotensin converting enzyme (ACE) activity and is not modulated by ACE inhibition;PLOS ONE;2022-02-03

5. Microalbuminuria among children and adolescents with sickle cell disease;Iraqi Journal of Hematology;2022